Distribuzione geografica
Continente #
EU - Europa 5257
NA - Nord America 5127
AS - Asia 2337
AF - Africa 42
OC - Oceania 30
SA - Sud America 24
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12822
Nazione #
US - Stati Uniti d'America 4920
CN - Cina 1659
SE - Svezia 819
IE - Irlanda 715
DE - Germania 676
UA - Ucraina 674
FR - Francia 581
IT - Italia 489
FI - Finlandia 468
KR - Corea 427
GB - Regno Unito 377
CA - Canada 204
PL - Polonia 174
AT - Austria 135
VN - Vietnam 119
DK - Danimarca 42
IN - India 30
BE - Belgio 28
NL - Olanda 28
AU - Australia 27
SN - Senegal 25
JP - Giappone 22
TW - Taiwan 19
IR - Iran 11
RU - Federazione Russa 11
BR - Brasile 10
HK - Hong Kong 10
TR - Turchia 10
EG - Egitto 9
TH - Thailandia 8
CH - Svizzera 6
CZ - Repubblica Ceca 6
CL - Cile 5
ES - Italia 5
LB - Libano 5
MU - Mauritius 5
NO - Norvegia 5
PH - Filippine 5
BG - Bulgaria 4
EU - Europa 4
PE - Perù 4
AR - Argentina 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
EC - Ecuador 2
GR - Grecia 2
HR - Croazia 2
ID - Indonesia 2
JO - Giordania 2
MX - Messico 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
DZ - Algeria 1
RO - Romania 1
RS - Serbia 1
SG - Singapore 1
SI - Slovenia 1
Totale 12822
Città #
Beijing 1304
Chandler 754
Dublin 671
Houston 610
Ann Arbor 445
Jacksonville 391
Villeurbanne 374
Princeton 258
Medford 239
Dearborn 172
Warsaw 170
Fairfield 159
Wilmington 142
Milan 136
Vienna 134
Toronto 132
Nyköping 130
Hangzhou 118
Boston 114
Woodbridge 96
Fremont 91
Verona 84
Ashburn 76
Redwood City 67
Dong Ket 60
Boardman 59
Seattle 54
Lachine 51
Cambridge 45
Pisa 44
Torino 43
Norwalk 38
Falls Church 36
Hefei 30
Menlo Park 26
Guangzhou 24
Munich 22
Redmond 20
Brussels 19
Shanghai 19
Kunming 18
Mountain View 17
Jinan 16
Detroit 15
Nanjing 15
San Diego 14
Shenyang 14
Taipei 14
Auburn Hills 13
Chicago 12
Tokyo 12
Chengdu 11
Düsseldorf 11
Monash 11
Hanoi 10
Zhengzhou 10
Phoenix 9
Philadelphia 8
Nanchang 7
Nürnberg 7
Seoul 7
Spokane 7
Austin 6
Fuzhou 6
Bologna 5
Helsinki 5
New York 5
Shenzhen 5
Taizhou 5
Turin 5
Arese 4
Bari 4
Bottanuco 4
Columbus 4
Des Moines 4
Gent 4
Hebei 4
Hyderabad 4
Istanbul 4
Paris 4
Rivoli 4
Rotterdam 4
Vancouver 4
Varese 4
Bangalore 3
Bangkok 3
Birmingham 3
Bonn 3
Changsha 3
Copenhagen 3
Desio 3
Fars 3
Grugliasco 3
Langfang 3
Lima 3
Mainz 3
Montréal 3
Newton Abbot 3
Oslo 3
Ottawa 3
Totale 7861
Nome #
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients 486
Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. 276
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease 193
Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study 172
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis 160
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen 160
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 145
[Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline] 141
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 137
Thyroid hormone levels in human breast cyst fluid. 134
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 130
Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features. 128
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 113
Adenohypophyseal hormone levels in the cerebrospinal fluid of patients with pituitary disease. 112
Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. 111
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. 107
Stage IB malignant thymoma in a Lynch syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil 104
Cations and dehydroepiandrosterone-sulfate in cyst fluid of pre- and menopausal patients with gross cystic disease of the breast. Evidence for the existence of subpopulations of cysts. 102
Confronto tra due metodi per la misura della concentrazione della cromogranina A circolante in pazienti con iperplasia prostatica benigna e adenocarcinoma prostatico 97
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial. 90
Cronochemioterapia dei tumori del colon-retto avanzati 89
Chromogranine A serum levels in patients affected by prostate cancer and benign prostate hypertrophy: comparison between two different commercial kits 88
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. 87
Melatonin and human cancer. 87
Apocrine cells in breast cyst fluid and their relationship to cyst type: a morphometric study. 86
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer 81
Circadian rhythm of breakthrough cancer pain. 80
[Cytostatic therapy of metastatic breast cancer] 79
Current status of hormonal therapy of fibrocystic breast disease. 78
A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study 78
The transition from pediatrics to adult medicine in patients recovered after an infantile neoplasm 77
Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception 76
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients 75
Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930. 74
Acute myeloblastic leukemia associated with mediastinal nonseminomatous germ cell tumors. Report on two cases. 74
Aggiornamenti in Cronochemioterapia 74
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. 73
Distúrbio Pós-Traumático de Stress, qualidade do sono, ansiedade, depressão e qualidade de vida em pacientes oncológicos em tratamento quimioterápico 73
Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia 72
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. 72
Differences between temporal patterns of plasma cortisol and corticosteroid-binding globulin binding capacity throughtout the twenty-four hour day and the menstrual cycle. 71
Biochemical picture of bone metabolism in breast cancer patients with bone metastases. 71
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy 71
Shifted distribution of cation-related cyst types in post-menopausal patients with gross cystic disease of the breast. 70
Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. 70
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. 69
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 67
[On the pituitary-inhibiting action and pharmacokinetics of some synthetic corticosteroids] 67
[Study of the distribution and metabolism of T4-I 125 and of T3-I 125 in the rat] 66
[Effect of 17-beta-estradiol on inhibition of corticosteroidogenesis obtained with metopirone] 65
[Acute effect of ACTH administered in vivo on the 11-beta-hydroxylase activity of rat adrenal gland homogenates] 65
[Rapid determination of total estrogens in pregnancy. Possibilities and limitations of the method] 65
Diagnostica per immagini 64
Background to and management of treatment-related bone loss in prostate cancer. 62
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. 61
[Endocrine therapy in breast carcinoma] 59
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome 59
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. 58
[Comparison between regional hemodynamics in the rat during barbiturate anesthesia and during ether anesthesia] 58
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects 58
Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast. 58
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy 58
[Regional hemodynamics in the rat: changes induced by administration of adrenaline and of a beta-blocking drug (INPEA)] 58
Cytotoxic chemotherapy for adrenocortical carcinoma. 58
Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer 57
[Influence of a beta-blocking drug on the clearance time of thyroxine-I-125 from plasma in rats] 57
A new magnesium-containing PEG-electrolyte solution for the oral lavage of the colon. 57
Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy 57
Risk of depressive events in long-term surviving patients affected by hormone-related cancer according to time after diagnosis 57
[Influence of adrenaline and a beta-blocking drug on distribution of thyroxine] 57
[Preliminary observations on the influence of thyroxine on the 11-beta-hydroxylase activity of homogenized extracts of rat adrenal glands in vitro] 56
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. 56
[Therapeutic use of corticosteroids] 56
The endocrine basis of benign breast disorders. 56
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, cremona, Italy (2010) 56
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. 56
Laparoscopic treatment of Morgagni-Larrey hernia: technical details and report of a series 55
Biochemistry of breast cyst fluid. An approach to understanding intercellular communication in the terminal duct lobular units. 55
Low dose CT in early lung cancer diagnosis: prevalence data 55
Cronochemioterapia dei tumori del colon retto metastatici 55
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). 55
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. 54
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. 54
The dopaminergic system and breast disease: novel approaches to pathophysiology and treatment. 54
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. 54
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer 53
Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P). 53
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 53
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly 53
Emerging drugs for adrenocortical carcinoma 53
Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy 53
Bisogni di cure palliative: i problemi dei pazienti con tumore nei loro ultimi mesi di vita. Un asurvey in 6 ASL piemontesi 53
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. 53
Il trattamento dell'ascite neoplastica: obiettivi e criteri di valutazione 53
[Studies of deiodination of thyroxine in vitro: effect of ATP and of cyanide] 52
Totale 8324
Categoria #
all - tutte 21258
article - articoli 0
book - libri 0
conference - conferenze 2189
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23447

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182253 0000 00 0596 10106111818
2018/20191150 265212133 40217 35149 607426281
2019/20202266 6486182201 232475 316139 22112915170
2020/20211526 1774318780 13263 17229 23214175195
2021/20221956 276669314 12259 23380 5384303546
2022/20231970 33317443211 223731 2550 0000
Totale 13392